Inflammatory bowel disease and demyelination: More than just a coincidence?

Expert Review of Clinical Immunology

Volumn 10, Issue 3, 2014, Pages 363-373

  Katsanos, Aristeidis H ^a   Katsanos, Konstantinos H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

anti TNF a; biological agents; Crohn's disease; demyelination; inflammatory bowel disease; monoclonal antibodies; multiple sclerosis; ulcerative colitis

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DEMYELINATING DISEASES; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; NEUROIMMUNOMODULATION; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894334419     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.885381     Document Type: Review

References (63)

1. Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013; 9(1):77-92
2. Sharma R, Sharma CL, Mahajan A. Biological agents targeting beyond TNFalpha. Indian J Crit Care Med 2008;12(4): 181-9
3. Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35(4): 837-55
4. Ryu YS, Park SH, Kim JM, et al. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. Rheumatol Int 2012;32(11):3481-55
5. Mercieca C, Vella N, Borg AA. Demyelination during anti-TNFa therapy for ankylosing spondylitis. Mod Rheumatol 2012;22(2):303-7
6. Ahmed Z, Powell R, Llewelyn G, Anstey A. Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF a therapy for chronic plaque psoriasis. BMJ Case Rep 2011;1:2011
7. Matsumoto T, Nakamura I, Miura A, et al. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol 2013;32(2):271-5
8. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012;64(9): 3043-51
9. Zois CD, Katsanos KH, Kosmidou M, Tsianos EV. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohns Colitis 2010;4(2):115-24
10. Deepak P, Stobaugh DJ, Sherid M, et al. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 2013;38(4):388-96
11. Singh S, Kumar N, Loftus EV Jr, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis 2013;19(4):864-72
12. Kararizou E, Davaki P, Speggos K, Stamboulis E. Rare association of polyneuropathy and Crohn's disease: a clinicopathological study of 4 cases. Pol J Pathol 2012;63(4):261-6
13. Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011;7(3):165-72
14. Alkhawajah MM, Caminero AB, Freeman HJ, Oger JJ. Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!. Mult Scler 2013;19(3):259-65
15. Green C, Elliott L, Beaudoin C, Bernstein CN. A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 2006;164(7):615-23.discussion 624-8
16. Cohen R, Robinson D Jr, Paramore C, et al. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008;14(6):738-43
17. Pokorny CS, Beran RG, Pokorny MJ. Association between ulcerative colitis and multiple sclerosis. Intern Med J 2007; 37(10):721-4
18. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-a), anti-TNF-a and demyelination revisited: an ongoing story. J Neuroimmunol 2011; 234(1-2):1-6
19. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325(7): 467-72
20. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47(6):1531-4
21. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53(3):457-65
22. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129(3):827-36
23. Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010;16(7): 855-61
24. Andersen NN, Caspersen S, Jess TMunkholm P. Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: a Danish Crohn Colitis Database study. J Crohns Colitis 2008;2(4):304-9
25. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006;92(1):60-4
26. Cantorna MT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys 2012;523(1):103-6
27. De Jager PL, Graham R, Farwell L, et al. The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus. Genes Immun 2006;7(4):327-34
28. Roos IM, Kockum I, Hillert J. The interleukin 23 receptor gene in multiple sclerosis: a case-control study. J Neuroimmunol 2008;194(1-2):173-80
29. Cenit MC, Alcina A, Marquez A, et al. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility. Genes Immun 2010;11(3):264-8
30. Martinez A, Sanchez-Lopez M, Varade J, et al. Role of the MHC2TA gene in autoimmune diseases. Ann Rheum Dis 2007;66(3):325-9
31. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012;488(7412):508-11
32. Illes Z, Safrany E, Peterfalvi A, et al. 3'UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. Neurosci Lett 2008; 431(1):36-8
33. Tsianos EV, Katsanos K. Do we really understand what the immunological disturbances in inflammatory bowel disease mean? World J Gastroenterol 2009;15(5): 521-5
34. Dubcenco E, Ottaway CA, Chen DL, Baker JP. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol 2006;18(5):565-6
35. Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol 2009;28(Suppl 1): S53-5
36. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129(3):819-26
37. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000;75(8):802-6
38. Oliveira GR, Teles BC, Brasil EF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis 2008;14(3):389-95
39. Tremlett HL, Evans J, Wiles CM, Luscombe DK. Asthma and multiple sclerosis: an inverse association in a case-control general practice population. QJM 2002;95(11):753-6
40. Marrie RA, Yu BN, Leung S, et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 2013;40(2):85-92
41. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126(1):19-31
42. Hamzaoglu H, Cooper J, Alsahli M, et al. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis 2010;16(12):2109-16
43. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6(11):1212-7; quiz 1176
44. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patientyears follow-up. Aliment Pharmacol Ther 2009;29(3):286-97
45. Felekis T, Katsanos K, Christodoulou D, et al. Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease. J Crohns Colitis 2009;3(3): 212-14
46. Freeman HJ, Flak B. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol 2005;19(5): 313-16
47. Gondim FA, Brannagan TH 3rd, Sander HW, et al. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 2005;128(Pt 4):867-79
48. Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54(5):1429-34
49. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009;66(4):490-7
50. Nozaki K, Silver RM, Stickler DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 2011;342(5):352-5
51. Ohyagi M, Ohkubo T, Yagi Y, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with Crohn's disease. Intern Med 2013;52(1): 125-8
52. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004;10(1):28-31
53. Aziz M, Stivaros S, Fagbemi A, Vassallo G. Acute disseminated encephalomyelitis in conjunction with inflammatory bowel disease. Eur J Paediatr Neurol 2013;17(2): 208-11
54. Bamford NS, Trojaborg W, Sherbany AA, De Vivo DC. Congenital Guillain-Barre syndrome associated with maternal inflammatory bowel disease is responsive to intravenous immunoglobulin. Eur J Paediatr Neurol 2002;6(2):115-19
55. Barabino AV, Gandullia P, Calvi A, et al. Sudden blindness in a child with Crohn's disease. World J Gastroenterol 2011;17(38): 4344-6
56. Charach G, Grosskopf I, Weintraub M. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 2008;77(3-4):198-200
57. Schott E, Paul F, Wuerfel JT, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007;13(26):3638-40
58. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106(9): 1594-602.quiz 1593, 1603
59. Keeley KA, Rivey MP, Allington DR. Natalizumab for the treatment of multiple sclerosis and Crohn's disease. Ann Pharmacother 2005;39(11):1833-43
60. Davenport RJMunday JR. Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today 2007;12(13-14):569-76
61. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009;23(1): 101-12
62. Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol 2007;3(5):683-94
63. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12(5): 543-53